10 Biotechnology Stocks to Sell Now

CVM, EPRS, OHRP, TSRX, VICL, TNXP, SGYP, VSTM, CLDX, TRVN slump in weekly rankings

The overall ratings of 10 biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

CEL-SCI Corporation’s (CVM) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. For more information, get Portfolio Grader’s complete analysis of CVM stock.

This week, EPIRUS Biopharmaceuticals, Inc.’s (EPRS) rating worsens to a D from the company’s C rating a week ago. The stock also rates an F in Earnings Revisions. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. To get an in-depth look at EPRS, get Portfolio Grader’s complete analysis of EPRS stock.

The rating of Ohr Pharmaceutical Inc (OHRP) declines this week from a C to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

Trius Therapeutics, Inc. (TSRX) gets weaker ratings this week as last week’s C drops to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

Slipping from a C to a D rating, Vical Incorporated (VICL) takes a hit this week. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of VICL stock.

The rating of Tonix Pharmaceuticals Holding Corp. (TNXP) slips from a C to a D. In Earnings Momentum, Earnings Surprise, Equity and Cash Flow the stock gets F’s. To get an in-depth look at TNXP, get Portfolio Grader’s complete analysis of TNXP stock.

Synergy Pharmaceuticals, Inc.’s (SGYP) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of Aug. 12, 2015, 23.6% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Verastem, Inc.’s (VSTM) rating weakens this week, dropping to an F versus last week’s D. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of Aug. 12, 2015, 12.5% of outstanding Verastem, Inc. shares were held short. Shares of the stock have been changing hands at an unusually rapid pace, four times the rate of the week prior. To get an in-depth look at VSTM, get Portfolio Grader’s complete analysis of VSTM stock.

Celldex Therapeutics, Inc. (CLDX) experiences a ratings drop this week, going from last week’s C to a D. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of Aug. 12, 2015, 16.6% of outstanding Celldex Therapeutics, Inc. shares were held short. Shares of the stock are being traded at a very rapid pace, up 709.1% from the week prior. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

This week, Trevena, Inc. (TRVN) drops from a C to a D rating. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at TRVN, get Portfolio Grader’s complete analysis of TRVN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/08/10-biotechnology-stocks-to-sell-now-cvm-eprs-ohrp-12/.

©2019 InvestorPlace Media, LLC